| Summary: | Background: Bezafibrate and Eicosapentanoic acid (EPA) were known to decrease serum triglyceride. And, EPA administration for 5 years was reported to improve cardiovascular events by JLIT study. Cardio-ankle vascular index (CAVI) was a new index reflecting arterial stiffness from the origin of the aorta to the ankle, and is reported to be a predictor of cardiac events or death rate of cardiovascular events. But, the effects of both agents on arterial stiffness were not fully clarified.
Object: The purpose of this paper is to clarify the effect of bezafibrate and EPA on the arterial stiffness monitored with CAVI in the type 2 diabetic patients with hypertriglyceridemia.
Subjects and methods: Eighty type 2 diabetic outpatients with hypertriglyceridemia were randomly divided into two groups: bezafibrate (BEZA; 400mg/day) and EPA (1800mg/day) groups and took each treatment for 6 months. Glucose and lipid metabolism, d-ROMs; an oxidative stress marker were also studied. CAVI was measured using Vasela1500 (Fukuda Denshi. Co.LTD).
Results: After 6 month treatment, blood pressure, LDL-cholesterol (LDL-C), CK were not significantly changed comparing with before values, in both groups. Triglyceride (TG) and remnant-like particle cholesterol decreased significantly in both groups, and there were no significant differences between groups. HDL-C, Apo A-1 increased and HbA1C, d-ROMs decreased significantly only in BEZA group. CAVI decreased by 0.1 in EPA group (not significant) and by 0.5 in BEZA group (p<0.005). There was a significant difference in the changes of CAVI between both groups (p<0.05). In BEZA group, there were no significant correlations between changes of CAVI and the changes of the other parameters.
Conclusion: Bezafibrate administration improved arterial stiffness monitored with CAVI significantly, whereas EPA administration did not changed CAVI, in type 2 diabetic patients with hypertriglyceridemia.
|
|---|
